79 related articles for article (PubMed ID: 35657703)
1. STAT3 promotes differentiation of monocytes to MDSCs via CD39/CD73-adenosine signal pathway in oral squamous cell carcinoma.
Cui H; Lan Z; Zou KL; Zhao YY; Yu GT
Cancer Immunol Immunother; 2023 May; 72(5):1315-1326. PubMed ID: 36436019
[TBL] [Abstract][Full Text] [Related]
2. DCLK1-Mediated Regulation of Invadopodia Dynamics and Matrix Metalloproteinase Trafficking Drives Invasive Progression in Head and Neck Squamous Cell Carcinoma.
Arnold L; Yap M; Jackson L; Barry M; Ly T; Morrison A; Gomez JP; Washburn MP; Standing D; Yellapu NK; Li L; Umar S; Anant S; Thomas SM
bioRxiv; 2024 Apr; ():. PubMed ID: 38645056
[TBL] [Abstract][Full Text] [Related]
3. Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes.
Terp MG; Gammelgaard OL; Vever H; Gjerstorff MF; Ditzel HJ
Mol Oncol; 2021 Dec; 15(12):3299-3316. PubMed ID: 34165921
[TBL] [Abstract][Full Text] [Related]
4. GRHL2 suppression of NT5E/CD73 in breast cancer cells modulates CD73-mediated adenosine production and T cell recruitment.
Coban B; Wang Z; Liao CY; Beslmüller K; Timmermans MAM; Martens JWM; Hundscheid JHM; Slutter B; Zweemer AJM; Neubert E; Danen EHJ
iScience; 2024 May; 27(5):109738. PubMed ID: 38706844
[TBL] [Abstract][Full Text] [Related]
5. Role of CD73 and the purinergic signaling pathway in the pathogenesis of fusion-negative rhabdomyosarcoma.
Fascì A; Deaglio S
Purinergic Signal; 2024 May; ():. PubMed ID: 38700722
[No Abstract] [Full Text] [Related]
6. Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit.
Kostecki KL; Iida M; Crossman BE; Salgia R; Harari PM; Bruce JY; Wheeler DL
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254801
[TBL] [Abstract][Full Text] [Related]
7. Effects of abnormal expression of CD73 on malignant phenotype of nasopharyngeal carcinoma.
Jiang B; Tang M; Shi S; Xie H; Pan S; Zhang L; Sheng J
J Mol Histol; 2023 Dec; 54(6):633-644. PubMed ID: 37874500
[TBL] [Abstract][Full Text] [Related]
8. Pan-cancer analysis of LINC02535 as a potential biomarker and its oncogenic role in lung adenocarcinoma.
Dai S; Liu T; He YY; Huang Y; Wang L; Luo F; Li Y
Heliyon; 2022 Dec; 8(12):e12108. PubMed ID: 36544816
[TBL] [Abstract][Full Text] [Related]
9. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
Front Immunol; 2022; 13():969034. PubMed ID: 36466881
[TBL] [Abstract][Full Text] [Related]
10. CD73 is associated with poor prognosis in HNSCC.
Ren ZH; Lin CZ; Cao W; Yang R; Lu W; Liu ZQ; Chen YM; Yang X; Tian Z; Wang LZ; Li J; Wang X; Chen WT; Ji T; Zhang CP
Oncotarget; 2016 Sep; 7(38):61690-61702. PubMed ID: 27557512
[TBL] [Abstract][Full Text] [Related]
11. The roles of CD73 in cancer.
Gao ZW; Dong K; Zhang HZ
Biomed Res Int; 2014; 2014():460654. PubMed ID: 25126561
[TBL] [Abstract][Full Text] [Related]
12. Roles of the HGF/Met signaling in head and neck squamous cell carcinoma: Focus on tumor immunity (Review).
Liu D; Zhong M; Zhan D; Zhang Y; Liu S
Oncol Rep; 2020 Dec; 44(6):2337-2344. PubMed ID: 33125120
[TBL] [Abstract][Full Text] [Related]
13. CD73 facilitates invadopodia formation and boosts malignancy of head and neck squamous cell carcinoma via the MAPK signaling pathway.
Xue F; Wang T; Shi H; Feng H; Feng G; Wang R; Yao Y; Yuan H
Cancer Sci; 2022 Aug; 113(8):2704-2715. PubMed ID: 35657703
[TBL] [Abstract][Full Text] [Related]
14. 5'-Ectonucleotidase CD73/NT5E supports EGFR-mediated invasion of HPV-negative head and neck carcinoma cells.
Shi E; Wu Z; Karaoglan BS; Schwenk-Zieger S; Kranz G; Abdul Razak N; Reichel CA; Canis M; Baumeister P; Zeidler R; Gires O
J Biomed Sci; 2023 Aug; 30(1):72. PubMed ID: 37620936
[TBL] [Abstract][Full Text] [Related]
15. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
Front Immunol; 2022; 13():975847. PubMed ID: 36091055
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
